Liposomal adjuvants for human vaccines

Area of Science:

• Vaccinology
• Nanotechnology
• Immunology

Background:

• Liposomes serve as essential drug carriers and are key components in licensed vaccine adjuvants.
• The field of liposomal vaccine adjuvants is characterized by continuous innovation and dynamism.
• Emerging commercial products and new vaccines highlight the evolving landscape of liposomal adjuvants.

Purpose of the Study:

• To examine the dynamic field of liposomal vaccine adjuvants.
• To discuss the potential for new vaccine types utilizing liposomal adjuvants.
• To explore alternative liposomal adjuvants for novel vaccine applications.

Main Methods:

• Virosomes composed of phospholipids and influenza virus proteins.
• Liposomes incorporating phospholipids, cholesterol, monophosphoryl lipid A, and QS21.
• Non-phospholipid cationic liposomes.
• Combinations of liposomes with immunostimulating ingredients for experimental vaccines.

Main Results:

• Liposomes with monophosphoryl lipid A and QS21 show significant promise for upcoming malaria, shingles, and cancer vaccines.
• Licensed virosome vaccines for influenza and hepatitis A are expected to be succeeded by vaccines for other infectious diseases.
• Alternative liposomal formulations are anticipated for challenging diseases like tuberculosis and HIV-1 infection.

Conclusions:

• Liposomal adjuvants are pivotal in advancing vaccine technology.
• Future vaccines for malaria, shingles, and cancer will likely leverage liposomal formulations.
• Liposomes offer a versatile platform for developing vaccines against a wide range of infectious diseases, including challenging ones like HIV-1 and tuberculosis.